Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Tonix Pharmaceuticals Holding Corp. roe for the quarter ending 2026-06-30 was -71.83%, a change of -23.37% year-over-year.
Tonix Pharmaceuticals Holding Corp. roe for the quarter ending 2026-03-31 was -64.89%, a change of 8.24% year-over-year.
Tonix Pharmaceuticals Holding Corp. roe for the quarter ending 2025-12-31 was -50.59%, a change of 42.59% year-over-year.
Tonix Pharmaceuticals Holding Corp. roe for the quarter ending 2025-09-30 was -42.93%, a change of 139.33% year-over-year.
Tonix Pharmaceuticals Holding Corp. roe for fiscal 2025 was -50.59%, a change of 42.59% from fiscal 2024.
Tonix Pharmaceuticals Holding Corp. roe for fiscal 2024 was -93.18%, a change of 17.37% from fiscal 2023.
Tonix Pharmaceuticals Holding Corp. roe for fiscal 2023 was -110.55%, a change of -57.35% from fiscal 2022.
Tonix Pharmaceuticals Holding Corp. roe for fiscal 2022 was -53.20%, a change of -11.00% from fiscal 2021.